Keyphrases
Solid Tumors
100%
Capecitabine
100%
Dose-escalation Study
100%
Indisulam
100%
Xeloda
100%
Recommended Dose
27%
Pharmacokinetics
18%
Cell Cycle Inhibitors
9%
Monotherapy
9%
Pharmacokinetic Analysis
9%
Pharmacokinetic Data
9%
Drug Interactions
9%
Plasma Concentration
9%
Dose-limiting Toxicity
9%
High Incidence
9%
Stable Disease
9%
Partial Response
9%
Hematotoxicity
9%
First Cycle
9%
Colon Adenocarcinoma
9%
Pancreatic Carcinoma
9%
Myelosuppression
9%
Multiple Treatments
9%
Treatment Cycle
9%
Pharmacokinetic Drug Interactions
9%
Hand-foot Syndrome
9%
Stomatitis
9%
Targeted Cells
9%
Time-dependent Pharmacokinetics
9%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Capecitabine
100%
Indisulam
100%
Pharmacokinetics
45%
Drug-Drug Interaction
18%
Disease
9%
Monotherapy
9%
Bone Marrow Suppression
9%
Colon Carcinoma
9%
Multiple Cycle Treatment
9%
Pancreas Carcinoma
9%
Hand Foot Syndrome
9%
Stomatitis
9%
Biochemistry, Genetics and Molecular Biology
Capecitabine
100%
Pharmacokinetics
50%
Recommended Drug Dose
30%
Drug Interaction
20%
Cell Cycle
10%
Colon
10%
Blood Level
10%
Metabolite
10%
Multiple Cycle Treatment
10%